<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199068</url>
  </required_header>
  <id_info>
    <org_study_id>CS7017-A-A110</org_study_id>
    <nct_id>NCT01199068</nct_id>
  </id_info>
  <brief_title>CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Phase 1b Study of CS-7017 in Combination With Erlotinib in Subjects With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC) Who Failed First-line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety and tolerability of CS-7017
      administered orally twice a day in combination with erlotinib, and to assess the
      pharmacokinetics of CS-7017 in combination with erlotinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>treatment continues until desease progression, unacceptable toxicity or consent withdrawal</time_frame>
    <description>Evaluate the safety and tolerability of CS-7017 in combination with erlotinib Number of subjects reporting Treatment Emergent Adverse Events (TEAEs), as a measure of safety and tolerability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma concentration of CS-7017</measure>
    <time_frame>10 weeks</time_frame>
    <description>To determine the plasma concentration of CS-7017 at Days 1, 8, 15, 22, 43, and 64 after study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>treatment-emergent Serious Adverse Events</measure>
    <time_frame>treatment continues until desease progression, unacceptable toxicity or consent withdrawal</time_frame>
    <description>Evaluate the safety and tolerability of CS-7017 in combination with erlotinib Number of subjects reporting treatment-emergent Serious Adverse Events (SAEs) as a measure of safety and tolerability.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>CS-7017+Erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: CS-7017 from 0.25 mg to 0.50 mg twice a daily Drug: Erlotinib 150 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-7017</intervention_name>
    <description>CS-7017 from 0.25 mg to 0.50 mg twice a daily</description>
    <arm_group_label>CS-7017+Erlotinib</arm_group_label>
    <other_name>CS7017</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 150 mg once daily</description>
    <arm_group_label>CS-7017+Erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed unresectable locally advanced or metastatic
             (stage IIIb or IV) Non-small Cell Lung Cancer (NSCLC)

          -  Recurrent disease (either no response to treatment or subsequent relapse after an
             objective response) that has progressed after first-line platinum based therapy

          -  Male or female ≥ 18 years of age

          -  Anticipation of more than 3 months survival

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 1

          -  Adequate organ and bone marrow function

        Exclusion Criteria:

          -  Prior Tyrosine Kinase Inhibitor (TKI) therapy

          -  Anticipation of need for a major surgical procedure or radiation therapy during the
             study

          -  Remaining influence of previous therapies such as radiotherapy, surgery, immunotherapy
             within 4 weeks prior to start of study treatment

          -  Treatment with anticancer medication within 4 weeks before study treatment, currently
             enrolled in another investigational drug study, or enrolled in another investigational
             drug study within 4 weeks of start of treatment

          -  History of any of the following events within 6 months prior to start of study
             treatment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral
             artery bypass graft, New York Heart Association (NYHA) class ≥I Congestive Heart
             Failure (CHF), cerebrovascular accident or cerebral infarction, pulmonary embolism,
             deep vein thrombosis, or other clinically significant thromboembolic event; clinically
             significant pulmonary disease (eg, severe Chronic-Obstructive Pulmonary Disease (COPD)
             or asthma)

          -  Severe edema, ascites fluid, pericardial or pleural effusion or pericardial
             involvement with the tumor within 6 months prior to start of study treatment, or which
             require steroid therapy/ diuretic therapy

          -  Subjects with brain metastasis (defined as untreated, symptomatic or requiring
             steroids or anticonvulsant medications to control associated symptoms)

          -  Subjects with clinically significant active infection which requires antibiotic
             therapy, or who are hepatitis B surface antigen (HBsAg)-, hepatitis C virus (HCV)- or
             human immunodeficiency virus (HIV)-positive or receiving antiretroviral therapy

          -  Subjects with malabsorption syndrome, chronic diarrhea (lasting over 4 weeks),
             inflammatory bowel disease, or partial bowel obstruction

          -  Diabetes mellitus requiring insulin, or a history of poor serum glucose control with
             the use of non-insulin diabetes medications

          -  Treatment with Thiazolidinedione(TZDs) within 4 weeks prior to start of study
             treatment

          -  History of a second malignancy, with the exception of in situ cervical cancer or
             adequately treated basal cell or squamous cell carcinoma of the skin

          -  Poorly-controlled blood pressure as judged by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-Gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <last_update_submitted>December 21, 2011</last_update_submitted>
  <last_update_submitted_qc>December 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PPAR gamma agonist</keyword>
  <keyword>Tumor</keyword>
  <keyword>Cancer</keyword>
  <keyword>Antineoplastic Agent</keyword>
  <keyword>Respiratory Tract Neoplasms</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Protein Kinase Inhibitors</keyword>
  <keyword>Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efatutazone</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

